Fetal growth disorders following medically assisted reproduction: due to maternal context or techniques? A national French cohort study.

Adverse child outcomes Assisted reproductive technologies Frozen embryo transfer IVF Large for gestational age Small for gestational age

Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
04 2023
Historique:
received: 01 09 2022
revised: 08 12 2022
accepted: 05 01 2023
medline: 7 4 2023
pubmed: 12 3 2023
entrez: 11 3 2023
Statut: ppublish

Résumé

What part do maternal context and medically assisted reproduction (MAR) techniques play in the risk of fetal growth disorders? This retrospective nationwide cohort study uses data available in the French National Health System database and focuses on the period from 2013 to 2017. Fetal growth disorders were divided into four groups according to the origin of pregnancy: fresh embryo transfer (n = 45,201), frozen embryo transfer (FET, n = 18,845), intrauterine insemination (IUI, n = 20,179) and natural conceptions (n = 3,412,868). Fetal growth disorders were defined from the percentiles of the weight distribution according to gestational age and sex: small and large for gestational age (SGA and LGA) if <10th and >90th percentiles, respectively. Analyses were performed using univariate and multivariate logistic models. Compared with births following natural conception, multivariate analysis showed that the risk of SGA was higher for births following fresh embryo transfer and IUI (adjusted odds ratio [aOR] 1.26 [1.22-1.29] and 1.08 [1.03-1.12], respectively) and significantly lower following FET (aOR 0.79 [0.75-0.83]). The risk of LGA was higher for births following FET (aOR 1.32 [1.27-1.38]), especially in artificial cycles when compared with ovulatory cycles (aOR 1.25 [1.15-1.36]). In the subgroup of births without any obstetrical or neonatal morbidity, the same increased risk of SGA and LGA were observed following fresh embryo transfer or IUI and FET (aOR 1.23 [1.19-1.27] or 1.06 [1.01-1.11] and aOR 1.36 [1.30-1.43], respectively). An effect of MAR techniques on the risks for SGA and LGA is suggested independently from maternal context and obstetrical or neonatal morbidities. Pathophysiological mechanisms remain poorly understood and should be further evaluated, as well as the influence of embryonic stage and freezing techniques.

Identifiants

pubmed: 36906455
pii: S1472-6483(23)00005-6
doi: 10.1016/j.rbmo.2023.01.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

739-749

Informations de copyright

Copyright © 2023 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Auteurs

Nathalie Sermondade (N)

Department of Reproductive Biology, Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: nathalie.sermondade@aphp.fr.

Laetitia Hesters (L)

Department of Reproductive Biology, Hôpital Antoine Béclère, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris, Clamart, France.

Jacques De Mouzon (J)

Unilabs, Direction Médicale, Clichy La Garenne, France.

Aviva Devaux (A)

Department of Reproductive Biology, Centre Hospitalier Universitaire, Amiens, France.

Sylvie Epelboin (S)

Department of Reproductive Medicine, Gynecology and Obstetrics, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris Nord, Université de Paris, Paris, France.

Patricia Fauque (P)

Université Bourgogne Franche-Comté-INSERM UMR1231, Dijon, France.

Marie-José Gervoise-Boyer (MJ)

Department of Reproductive Medicine, Hôpital Saint Joseph, Marseille, France.

Julie Labrosse (J)

Department of Reproductive Medicine, Gynecology and Obstetrics, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris Nord, Université de Paris, Paris, France.

Géraldine Viot (G)

Unité de Génétique Clinique de La Muette, Paris, France.

Marianne Bergère (M)

Agence de la Biomédecine, La Plaine Saint Denis, France.

Claire Devienne (C)

Agence de la Biomédecine, La Plaine Saint Denis, France.

Philippe Jonveaux (P)

Agence de la Biomédecine, La Plaine Saint Denis, France.

Rachel Levy (R)

Department of Reproductive Biology, Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Assistance Publique-Hôpitaux de Paris, Paris, France.

Fabienne Pessione (F)

Agence de la Biomédecine, La Plaine Saint Denis, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH